EE200000621A - Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine - Google Patents

Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine

Info

Publication number
EE200000621A
EE200000621A EEP200000621A EEP200000621A EE200000621A EE 200000621 A EE200000621 A EE 200000621A EE P200000621 A EEP200000621 A EE P200000621A EE P200000621 A EEP200000621 A EE P200000621A EE 200000621 A EE200000621 A EE 200000621A
Authority
EE
Estonia
Prior art keywords
preparation
picornaviral
compounds
picornaviral compounds
Prior art date
Application number
EEP200000621A
Other languages
English (en)
Inventor
Scott Dragovich Peter
Timothy Marakovits Joseph
Jay Prins Thomas
Girish Tikhe Jayashree
Evan Webber Stephen
Zhou Ru
O. Johnson Theodore
Original Assignee
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of EE200000621A publication Critical patent/EE200000621A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EEP200000621A 1998-04-30 1999-01-05 Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine EE200000621A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8382898P 1998-04-30 1998-04-30
US9835898P 1998-08-28 1998-08-28
PCT/US1999/000260 WO1999057135A1 (en) 1998-04-30 1999-01-05 Antipicornaviral compounds, their preparation and use

Publications (1)

Publication Number Publication Date
EE200000621A true EE200000621A (et) 2002-06-17

Family

ID=26769788

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000621A EE200000621A (et) 1998-04-30 1999-01-05 Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine

Country Status (34)

Country Link
US (3) US6531452B1 (et)
EP (1) EP1073672B1 (et)
JP (1) JP2003526600A (et)
KR (1) KR20010043004A (et)
CN (1) CN1198838C (et)
AP (1) AP2000001934A0 (et)
AT (2) ATE248186T1 (et)
AU (1) AU768539B2 (et)
BG (1) BG104899A (et)
BR (1) BR9910573A (et)
CA (1) CA2326763A1 (et)
DE (2) DE69928140D1 (et)
DK (1) DK1073672T3 (et)
EA (1) EA003856B1 (et)
EE (1) EE200000621A (et)
ES (1) ES2205760T3 (et)
GE (1) GEP20022824B (et)
HK (1) HK1034722A1 (et)
HR (1) HRP20000623A2 (et)
HU (1) HUP0400624A2 (et)
IL (1) IL138609A0 (et)
IS (1) IS5633A (et)
LT (1) LT4846B (et)
LV (1) LV12666B (et)
NO (1) NO20005411L (et)
NZ (1) NZ507633A (et)
OA (1) OA11503A (et)
PL (1) PL351250A1 (et)
PT (1) PT1073672E (et)
SI (1) SI20428A (et)
SK (1) SK284714B6 (et)
TR (1) TR200003159T2 (et)
WO (1) WO1999057135A1 (et)
YU (1) YU66000A (et)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198838C (zh) 1998-04-30 2005-04-27 阿格罗尼制药公司 抗小rna病毒化合物及其制备方法和用途
US6355807B1 (en) 1999-08-24 2002-03-12 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
PE20010517A1 (es) * 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
US6774243B2 (en) 1999-08-24 2004-08-10 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
PA8507801A1 (es) 1999-12-03 2002-08-26 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis
PA8515201A1 (es) 2000-04-14 2002-10-24 Agouron Pharma Compuestos y composiciones antipicornavirales; sus usos farmaceuticos y los materiales para su sintesis
WO2001096297A2 (en) * 2000-06-14 2001-12-20 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
WO2004093860A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Inhibitors of sars related coronavirus proteinase
US20040235952A1 (en) * 2003-05-05 2004-11-25 Agouron Pharmaceuticals, Inc. Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
US7462594B2 (en) 2003-12-31 2008-12-09 Taigen Biotechnology Co., Ltd. Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
EP1704142A4 (en) * 2003-12-31 2008-08-20 Taigen Biotechnology Co Ltd PROTEASE INHIBITORS
CN100363346C (zh) * 2004-10-22 2008-01-23 清华大学 冠状病毒主蛋白酶的小分子抑制剂、制备方法及其应用
US7893657B2 (en) * 2006-12-19 2011-02-22 Anand Kumar Chavakula Multi-power charger and battery backup system
KR100891699B1 (ko) 2007-04-10 2009-04-03 광주과학기술원 7-아미노-4-((ｓ)-3-(4-플루오로페닐)-2-((r)-3-메틸-2-(5-메틸이소옥사졸-3-카복사미도)부탄아미도)프로판아미도)-7-옥소-2-헵테노에이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 및 치료용 약학적 조성물
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
AU2009250295B2 (en) 2008-05-21 2014-05-01 Genesis Technologies Limited Selective caspase inhibitors and uses thereof
US9045524B2 (en) 2009-05-21 2015-06-02 Novagenesis Foundation Selective caspase inhibitors and uses thereof
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
EP2697246B1 (en) * 2011-04-15 2018-03-07 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
CN102838523A (zh) * 2011-06-23 2012-12-26 南开大学 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
CN103145608B (zh) * 2011-12-07 2015-09-02 南开大学 抗肠病毒71(ev71)己内酰胺类化合物及其制备方法和用途
RU2518314C2 (ru) 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
CN110105348A (zh) * 2019-03-08 2019-08-09 南开大学 新型迈克尔受体类肠病毒71型抑制剂的制备及用途
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
JP2021138694A (ja) 2020-03-06 2021-09-16 ファイザー・インク ＳＡＲＳ−ＣｏＶ−２複製を阻害し、コロナウイルス疾患２０１９を処置する方法
CN116648240A (zh) * 2021-01-22 2023-08-25 中国人民解放军军事科学院军事医学研究院 一种环肽类病毒蛋白酶抑制剂，其制备方法，及其在抗病毒药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652676A (en) 1985-05-06 1987-03-24 General Foods Corporation L-aminodicarboxylic acid alkenes
JPH06510986A (ja) 1991-06-14 1994-12-08 カイロン　コーポレイション ピコルナウイルスプロテアーゼのインヒビター
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
IT1269511B (it) 1994-05-17 1997-04-01 Univ Degli Studi Milano Derivati di acidi ammino-solfonici , loro impiego nella sintesi di pseudopeptidi e procedimento per la loro preparazione
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
IT1281031B1 (it) 1995-11-17 1998-02-11 Carlo Chiaves Struttura prefabbricata per la realizzazione di opere costruite a cielo aperto, particolarmente per cavalcavia autostradali,
TW442452B (en) 1996-03-01 2001-06-23 Akzo Nobel Nv Serine protease inhibitors having an alkynylamino side chain
EP0910572B1 (en) * 1996-05-14 2005-04-27 Agouron Pharmaceuticals, Inc. Inhibitors of picornavirus 3c proteases and methods for their use and preparation
US5856530A (en) 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
WO1997049668A1 (en) 1996-06-13 1997-12-31 Smithkline Beecham Corporation Inhibitiors of cysteine protease
US6020371A (en) 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
US6331554B1 (en) 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
ES2206907T3 (es) * 1997-03-28 2004-05-16 Agouron Pharmaceuticals, Inc. Compuestos anti-picornavirus, composiciones que contienen estos compuestos y sus procedimientos de utilizacion.
US5962487A (en) 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
CN1198838C (zh) 1998-04-30 2005-04-27 阿格罗尼制药公司 抗小rna病毒化合物及其制备方法和用途
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
PL354030A1 (en) 1999-08-04 2003-12-15 Agouron Pharmaceuticals, Inc.Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
PE20010517A1 (es) 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
IL147862A0 (en) 1999-08-24 2002-08-14 Agouron Pharma Process and intermediates for the preparation os isoxazolecaroxamides and analogues
PA8507801A1 (es) 1999-12-03 2002-08-26 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis

Also Published As

Publication number Publication date
AU768539B2 (en) 2003-12-18
EA200001133A1 (ru) 2001-08-27
IL138609A0 (en) 2001-10-31
US20060046966A1 (en) 2006-03-02
US20030130204A1 (en) 2003-07-10
CN1311793A (zh) 2001-09-05
NO20005411D0 (no) 2000-10-27
ES2205760T3 (es) 2004-05-01
WO1999057135A1 (en) 1999-11-11
IS5633A (is) 2000-09-22
ATE248186T1 (de) 2003-09-15
HRP20000623A2 (en) 2001-04-30
OA11503A (en) 2004-05-10
KR20010043004A (ko) 2001-05-25
YU66000A (sh) 2003-12-31
CA2326763A1 (en) 1999-11-11
TR200003159T2 (tr) 2001-09-21
SK284714B6 (sk) 2005-09-08
CN1198838C (zh) 2005-04-27
EP1073672A1 (en) 2001-02-07
JP2003526600A (ja) 2003-09-09
BR9910573A (pt) 2001-01-16
BG104899A (en) 2001-08-31
US6995142B2 (en) 2006-02-07
DE69910762D1 (de) 2003-10-02
EP1073672B1 (en) 2003-08-27
LT4846B (lt) 2001-10-25
LV12666A (en) 2001-05-20
DE69910762T2 (de) 2004-03-11
SI20428A (sl) 2001-06-30
US6531452B1 (en) 2003-03-11
HK1034722A1 (en) 2001-11-02
LV12666B (lv) 2001-11-20
HUP0400624A2 (hu) 2004-06-28
EA003856B1 (ru) 2003-10-30
NO20005411L (no) 2000-10-27
GEP20022824B (en) 2002-10-25
DE69928140D1 (de) 2005-12-08
SK16042000A3 (sk) 2001-05-10
DK1073672T3 (da) 2003-12-08
AU2028799A (en) 1999-11-23
AP2000001934A0 (en) 2000-12-31
NZ507633A (en) 2003-10-31
ATE308557T1 (de) 2005-11-15
PL351250A1 (en) 2003-04-07
LT2000109A (en) 2001-05-25
PT1073672E (pt) 2004-01-30

Similar Documents

Publication Publication Date Title
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
EE04849B1 (et) Asendatud fenüülderivaadid, nende valmistamine jakasutamine
EE200200175A (et) Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
ID25977A (id) Popok sekali pakai
ID24555A (id) Popok sekali pakai
ID23076A (id) Popok sekali pakai
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
IS5699A (is) Ný notkun
EE200100009A (et) Bensimidasoolid, nende valmistamine ja kasutamineravimitena
EE200000037A (et) Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena
FI103704B1 (fi) Mikrobinvastainen koostumus, sen valmistusmenetelmä ja sen käyttö
ID23083A (id) Popok sekali pakai
EE200100347A (et) 3,3-biarüülpiperidiini ja 2,2-biarüülmorfoliini derivaadid
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse
FI971317A0 (fi) Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
IS5877A (is) Ný efnablanda
ID26780A (id) Senyawa-senyawa tienopiridina, hasil dan kegunaannya
IS5879A (is) Ný efnablanda
TH117427B (th) สารประกอบออกซีม, การใช้ประโยชน์สารเหล่านั้น และสารขั้นกลางสำหรับใช้เตรียมสารเหล่านั้น
DK1127052T3 (da) Substituerede 2-phenylbenzimidazoler, fremstilling og anvendelse heraf
DE29819078U1 (de) Glucuron Präparat
DE29805469U1 (de) Peloidzubereitung
DK0991725T3 (da) Azopigmentsammensætning, dens fremstilling og anvendelse